Hospital General Universitario Gregorio Maranon
Verified site
Madrid, Spain
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
The study looks at children from birth to less than 18 years who have a bloodstream infection called Staphylococcus aureus bacteremia. This infection can sometimes spread to the heart valves, causing right-sided infective endocarditis. The trial compares a new antibiotic, ceftobiprole, given as a drip, with the usual medicines doctors normally use, called the standard-of-care. The main purpose is to find out if the new drug is safe for children and works as well as the usual treatment. “Pharmacokinetics” means how the drug moves through the body, including how it is absorbed, spread, broken down, and removed.
Children who meet the study rules are randomly assigned to receive either the new drug or the usual treatment, and neither the doctors who decide care nor the staff who record results know which child got which medicine. The medication is given by an intravenous infusion for a set number of days, after which the children are checked at several visits to see how they feel, if any side effects occurred, and whether the infection cleared. Follow‑up continues for about a month after the last dose to monitor safety and overall recovery.
The trial runs in 9 steps – from screening to follow-up. Each step says what happens and what the team monitors.
5 criteria
21 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Madrid, Spain
Madrid, Spain
Esplugues De Llobregat, Spain
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not yet recruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
is an antibiotic that is given through a vein (intravenous infusion). It is used to treat infections caused by the bacteria Staphylococcus aureus, including serious blood infections (bacteremia) and infections of the heart lining (right‑sided infective endocarditis). In this study, the medicine is being tested to see how safe it is for children from birth up to 18 years old, and how well it works compared with the usual treatments.
refers to the usual antibiotics and medical care that doctors normally give to children with Staphylococcus aureus bacteremia and related infections. These treatments are the current best practice and are used as a comparison to see if the new medication, ceftobiprole, offers any advantages in safety or effectiveness.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.